Reported Saturday, Roche's B7-H3-Targeted ADC Tam-Peli Meets Primary Endpoint In Phase III TAISHAN-302 Trial, China's NMPA Accepts New Drug Application For Filing
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving
Roche's new cancer medicine worked better than an older drug in China testing. When a company's medicine passes big tests, it shows they are making progress.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.